PDE inhibitors, in particular the PDE5 (cyclic GMP PDE) inhibitors avanafil, lodenafil, sildenafil, tadalafil, udenafil and vardenafil, are regarded as efficacious, having a fast onset of drug ...

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces the development of novel pan-KRAS inhibitors of new chemotypes through ...

Transpire Bio has licensed an inhaled PDE4 inhibitor from China’s Intragrand Pharma as a potential treatment for idiopathic pulmonary fibrosis.

About ERAS-4001 ERAS-4001 is an oral, highly potent, and selective pan-KRAS inhibitor with a potential first-in-class and best-in-class profile.

Nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B) with antifibrotic and immunomodulatory effects, a mechanism different than approved antifibrotic treatments pirfenidone ...

While other PDE4 inhibitors have been studied for pain unrelated to alcohol consumption, apremilast may offer a path toward more personalized therapies for those with both AUD and pain.

InnoCare Announces the Acceptance of New Drug Application for pan-TRK Inhibitor Zurletrectinib in China Provided by Business Wire Apr 15, 2025, 5:30:00 PM ...

A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.

Pancreatic ductal adenocarcinoma (PDAC) has a low 5-year survival rate of <12%. Even though KRAS is mutated in about 88% of PDACs, the KRAS G12C mutation is rare, limiting the use of KRAS G12C ...